Article
Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Oncotarget - 21 Aug 2015
Boland Genevieve M, Piha-Paul Sarina A, Subbiah Vivek, Routbort Mark, Herbrich Shelley M, Baggerly Keith, Patel Keyur P, Brusco Lauren, Horombe Chacha, Naing Aung, Fu Siqing, Hong David S, Janku Filip, Johnson Amber, Broaddus Russell, Luthra Raja, Shaw Kenna, Mendelsohn John, Mills Gordon B, Meric-Bernstam Funda
Abstract excerpt
PURPOSE: We determined the frequency of recurrent hotspot mutations in 46 cancer-related genes across tumor histologies in patients with advanced cancer. METHODS: We reviewed data from 500 consecutive patients who underwent genomic profiling on an IRB-approved prospective clinical protocol in the Phase I program at the MD Anderson Cancer Center. Archival tumor DNA was tested for 740 hotspot mutations in 46 genes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.